© MDTB Cells GmbH - All Rights Reserved
This presentation contains “forward‐looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding MDTB Cells GmbH’s/ MDTB Cell Manufacturing GmbH’s business strategy, future regulatory approvals, pipeline developments, manufacturing scalability, target markets, and projected financial performance. Forward‐looking statements involve risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied. Factors that could cause our actual results to differ include, but are not limited to, clinical trial outcomes, regulatory review timelines, manufacturing challenges, market acceptance of cell therapies, and general economic conditions.
This document is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction. Any offering of securities will be made only by means of a definitive private placement memorandum and in compliance with applicable securities laws. Recipients of this presentation agree to keep its contents confidential and not to reproduce, distribute, or use this material for any purpose other than evaluating a potential investment in MDTB Cell Manufacturing GmbH.
MDTB Cell Manufacturing GmbH undertakes no obligation to update or revise any forward‐looking statements in this presentation, whether as a result of new information, future events, or otherwise.
